Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
VERA THERAPEUTICS INC (VERA) Stock Price & Overview
NASDAQ:VERA • US92337R1014
Current stock price
35.2 USD
-0.41 (-1.15%)
At close:
35.14 USD
-0.06 (-0.17%)
After Hours:
The current stock price of VERA is 35.2 USD. Today VERA is down by -1.15%. In the past month the price decreased by -13.85%. In the past year, price increased by 39.08%.
VERA Key Statistics
52-Week Range18.76 - 56.05
Current VERA stock price positioned within its 52-week range.
1-Month Range34.6737 - 47
Current VERA stock price positioned within its 1-month range.
- Market Cap
- 2.524B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.66
- Dividend Yield
- N/A
VERA Stock Performance
Today
-1.15%
1 Week
-6.61%
1 Month
-13.85%
3 Months
-18.63%
Longer-term
6 Months +23.68%
1 Year +39.08%
2 Years -7.34%
3 Years +321.56%
5 Years +104.06%
10 Years N/A
VERA Stock Chart
VERA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VERA. When comparing the yearly performance of all stocks, VERA turns out to be only a medium performer in the overall market: it outperformed 58.8% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
VERA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERA. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VERA Earnings
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.39
Revenue Reported
EPS Surprise -6.33%
Revenue Surprise %
VERA Forecast & Estimates
20 analysts have analysed VERA and the average price target is 79.72 USD. This implies a price increase of 126.47% is expected in the next year compared to the current price of 35.2.
Analysts
Analysts85
Price Target79.72 (126.48%)
EPS Next Y-14.5%
Revenue Next YearN/A
VERA Index Membership
VERA is currently included in the following stock indexes tracked on ChartMill.
VERA Financial Highlights
Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -4.66. The EPS decreased by -69.45% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-299.62M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.78% | ||
| ROE | -49.56% | ||
| Debt/Equity | 0.12 |
Chartmill High Growth Momentum
EPS Q2Q%-93.06%
Sales Q2Q%N/A
EPS 1Y (TTM)-69.45%
Revenue 1Y (TTM)N/A
VERA Ownership
Ownership
Inst Owners114.96%
Shares71.71M
Float70.63M
Ins Owners1.24%
Short Float %13.98%
Short Ratio8.04
VERA Industry Overview
VERA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
VERA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VERA
Company Profile
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 249 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
Company Info
IPO: 2021-05-14
VERA THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 1200
Brisbane California CALIFORNIA 14623 US
CEO: Marshall Fordyce
Employees: 249
Phone: 13026587581
VERA THERAPEUTICS INC / VERA FAQ
What does VERA THERAPEUTICS INC do?
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 249 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
Can you provide the latest stock price for VERA THERAPEUTICS INC?
The current stock price of VERA is 35.2 USD. The price decreased by -1.15% in the last trading session.
What is the dividend status of VERA THERAPEUTICS INC?
VERA does not pay a dividend.
How is the ChartMill rating for VERA THERAPEUTICS INC?
VERA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of VERA stock?
VERA THERAPEUTICS INC (VERA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for VERA THERAPEUTICS INC?
VERA THERAPEUTICS INC (VERA) has a market capitalization of 2.52B USD. This makes VERA a Mid Cap stock.
When does VERA THERAPEUTICS INC (VERA) report earnings?
VERA THERAPEUTICS INC (VERA) will report earnings on 2026-05-04.